Sanofi | 6-K: New Phase 2b Results for Amlitelimab Support Potential for Best-in-Class Maintenance of Response in Atopic Dermatitis
Sanofi | S-8 POS: S-8 POS
Sanofi | 6-K: Colletion of Recent Announcements
Sanofi | IRANNOTICE: IRANNOTICE
Sanofi | 20-F: Registration statement / Annual report / Transition report
Sanofi | 6-K: Peer Support, Flexible Work Arrangements, Salary for a Year: Sanofi Launches Global Program for Employees Affected by Cancer and Critical Illnesses
Sanofi | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)
Sanofi | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Dodge & Cox(4.9%)
Sanofi | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(7.2%)
Sanofi | 6-K: Dupixent® FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) and François-Xavier Roger Appointed Chief Financial Officer, Member of Sanofi Executive Committee
Sanofi | 6-K: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
Sanofi | 6-K: Sanofi to Acquire Inhibrx, Inc., Adding Potential Best-in-Class Rare Disease Asset for Alpha-1 Antitrypsin Deficiency to Pipeline
Sanofi | 6-K: Brian Foard Appointed Head of Specialty Care Global Business Unit, Member of Sanofi Executive Committee
Sanofi | 6-K: Sanofi Announces End of Program Evaluating Tusamitamab Ravtansine After a 2L NSCLC Phase 3 Trial Did Not Meet a Primary Endpoint
Sanofi | 6-K: Colletion of Recent Announcements
Sanofi | F-6EF: Auto effective registration statement for American Depositary Receipts representing securities of certain foreign private issuers
Sanofi | 6-K: Dupixent® Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
Sanofi | SC 13G: Statement of acquisition of beneficial ownership by individuals-SANOFI(7.4%)
Sanofi | 6-K: Specialty Care Growth, Strong Launch Uptake of Beyfortus® and ALTUVIIIO® Drive Solid Q3 Results
Sanofi | 6-K: Sanofi Enters Next Chapter of Play to Win Strategy
No Data